Effect of Ketanserin on Hemodynamics, Plasma-Catecholamine Concentrations, and Serotonin Uptake by Platelets in Volunteers and Patients with Congestive Heart Failure

H. Grobecker, I. Gessler, *W. Delius, P. Dominiak, and F. Kees

Department of Pharmacology, University of Regensburg, Regensburg, and *Department of Cardiology, Bogenhausen Hospital, Munich, Federal Republic of Germany

Summary: Ketanserin, which preferentially blocks 5-HT₂-serotonergic receptors, was injected intravenously (i.v.) to patients with congestive heart failure in a bolus dose of 10 mg, followed by an i.v. infusion of 3 mg/h over a period of 4 h. The drug caused a decrease in total peripheral resistance and, conversely, an increase in stroke volume. Right atrial and pulmonary artery pressures were decreased. Plasma noradrenaline rose twofold over the basal levels shortly after injection, but showed a distinct fall 2 h after beginning of the treatment. The concentrations of ketanserin in plasma after bolus injection approximated 100–150 ng/mL. The sympathono- and sympathoadrenal reaction during tilting were increased after i.v. injection of 10 mg ketanserin in volunteers. The noradrenaline and adrenaline levels in plasma rose significantly more when compared with values before the injection of the drug. In vitro as well as in vivo ketanserin exerts a concentration-dependent inhibitory effect on the active transport of serotonin and catecholamines (dopamine, noradrenaline, adrenaline) into human platelets. Considering platelets as a model of the sympathetic neurons, the inhibition of uptake of catecholamines by ketanserin could contribute to the observed increase in circulating catecholamines after injection of the drug. Key Words: Ketanserin—Hemodynamics—Congestive heart failure—Volunteers—Plasma catecholamines—Blood platelets.

Ketanserin is a quinazoline derivative that blocks vasoconstriction induced by serotonin in various animal models (1). Binding to 5-HT₂-serotonergic receptors correlates both in vitro and in vivo with the peripheral pharmacological and physiological effects of serotonin (2). As ketanserin is used for the treatment of hypertension (3), it was of interest to investigate the hemodynamic effects of the drug both in patients with congestive heart failure and in healthy volunteers. In addition, investigations on uptake of biogenic amines in human platelets, as a model of sympathetic neurons, has been performed. Our data show that ketanserin is capable of lowering total peripheral resistance, increasing stroke volume, and inhibiting active uptake of serotonin and catecholamines by platelets.

PATIENTS, VOLUNTEERS, AND METHODS

Twenty patients were studied, nine men and 11 women [mean age, 64 years (range 47–80 years)] (New York Heart Association, stage III–IV). The diagnosis of congestive heart failure was established by routine screening. Measurement of cardiac output was performed with thermodilution. Right atrial and pulmonary artery pressures were measured. Total peripheral resistance was calculated. Heart rate and blood pressure were determined continuously. Ten milligrams of ketanserin was injected i.v. as a bolus within 15 min. Subsequently the drug was infused intravenously (i.v.) 3 mg/h over a period of 4 h. Blood samples for radioenzymatic determination of catecholamines (4) were obtained from a cubital vein. Six healthy volunteers, ages 25–35 years, were investigated. Blood platelets were prepared and incubated before and after injection of 10 mg ketanserin i.v. as described previously (5). Tilting was performed on an automatic table moving the volunteers from the horizontal to the vertical plane (45°).

RESULTS

In patients with congestive heart failure, the i.v. injection of ketanserin caused a significant fall in total peripheral resistance and a significant increase in cir-
norepinephrine from 250 ± 20 to 560 ± 60 pg/ml (p < 0.01 SEM). Adrenaline levels were not changed. After injection of ketanserin and subsequent tilting, noradrenaline levels rose to 1,400 ± 200 pg/ml and adrenaline levels rose from 50 ± 15 (controls in supine position) to 105 ± 18 pg/ml (p < 0.01). Circulating dopamine did not change before and after administration of ketanserin.

In vitro uptake of [14C]serotonin by human platelets was inhibited by increasing concentrations of ketanserin (IC50 = 5 × 10−5 M; incubation time: 5 min). In addition, uptake of catecholamines by platelets was blocked by ketanserin, as shown in Table 1. Also, uptake of serotonin by platelets obtained from blood samples of a contralateral vein 1 or 5 min after i.v. injection of 10 mg ketanserin was considerably diminished (control: 40 × 10−2 cpm/[14C]serotonin/108 platelets; 1 min after injection of ketanserin: 8 × 10−2 cpm/[14C]serotonin/108 platelets; incubation time 5 min).

**DISCUSSION**

The results of this study in humans confirm experimental observations that ketanserin is able to induce vasodilation possibly by blockade of 5-HT1 receptors, thereby diminishing enhanced peripheral resistance, e.g., in patients with congestive heart failure. Reducing the afterload of the impaired heart resulted in an increased stroke volume. This might have therapeutic implications in the treatment of congestive heart failure. Considering the mechanism of vasodilation, a blockade of peripheral postsynaptic α1-adrenoceptors by ketanserin cannot be excluded, as the concentrations of ketanserin in plasma reached values more than 100 pg/ml. In line with this assumption is the impaired sympathetic counter-regulation in volunteers during tilting under the influence of ketanserin. In this context, it is also of interest that, in animal experiments, a stimulation of central α1-adrenoceptors by ketanserin resulted in inhibition of total peripheral sympathetic outflow (7).

In vitro as well as in vivo ketanserin exerted a concentration/dose-dependent inhibition of uptake of serotonin and catecholamines (dopamine, norepinephrine, adrenaline) by platelets (Table 1). However, the concentrations of ketanserin for half-maximum inhibition are

<table>
<thead>
<tr>
<th>TABLE 1. Effect of ketanserin on active uptake of catecholamines by human platelets in plasma in vitro</th>
</tr>
</thead>
<tbody>
<tr>
<td>Concentration of ketanserin (M)</td>
</tr>
<tr>
<td>---------------------------------</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>10−8</td>
</tr>
<tr>
<td>10−7</td>
</tr>
<tr>
<td>10−6</td>
</tr>
<tr>
<td>Incubation 60 min at 37°C</td>
</tr>
</tbody>
</table>

CA, catecholamine; DA, dopamine; NA, norepinephrine; A, adrenaline

J Cardiovasc Pharmacol. Vol. 7 (Suppl. 7), 1985
higher than those needed for blockade of either peripheral postsynaptic α₁-adrenoceptors or serotoninergic (5-HT₂) receptors. Considering platelets as a model of the sympathetic neuron, however, inhibition of reuptake of catecholamines by ketanserin could possibly contribute to the observed increase in circulating catecholamines shortly after injection of the drug.

REFERENCES


